Ovarian Cancer accounts for about 3% of cancers among women, but it causes more deaths than any other cancers of the female reproductive system. Recurrent Ovarian Cancer is almost always fatal, and new treatments are desperately needed.
Researchers at the University of Arizona, Tucson Cancer Center have discovered an improved treatment for Ovarian Cancer, which can increase the rate of tumor shrinkage and prolong the time until cancers recur.
The novel treatment, Trebananib, is a first-in-class peptide-Fc fusion protein that inhibits the binding of both angiopoietin 1 and 2 to Tie2 receptor that targets angiogenesis, which is a process of the growth of new blood vessels in cancerous tumors.
Angiogenesis is a complex process in oncology, and the growth of new blood vessels are very important for cancer growth, metastases, and progression. Trebananib aims to choke off the cancerous tumors’ blood supply to stop their growth.
Unlike the traditional Ovarian Cancer treatment, Bevaciuzmab, Trebananib does not increase the risk of hypertension and bowel perforation, but it has a similar impact on tumor shrinkage and significantly delays cancer progression.
The novel treatment has been added to TRINOVA-1, which is a randomized prospective phase III clinical trial for Ovarian Cancer. TRINOVA-1 has been applied among 919 women with recurrent ovarian cancer from 179 sites in 32 countries.
Novel Discoveries Help Attract Significant Amount of Research Funds at UA
The University of Arizona Health System helps treat more than 100,000 patients each year, and the University of Arizona Cancer Center is the only comprehensive cancer center headquartered in Arizona. The University of Arizona, Tucson is home to numerous life science research programs, which collaborate a breadth of issues from laboratory ideas to bedside care with a major emphasis on discovery.
Each year the University of Arizona attracts more than $600 million in research funding. In 2013 the University of Arizona,Tucson received grants of $74 million in research from the National Institutes of Health and more than $38 million as of July 1st 2014.
BCI: Create Connections with the University of Arizona
Biotechnology Calendar, Inc. (BCI) is providing an opportunity for laboratory supply companies to connect with academic researchers at the University of Arizona at the 12th Annual BioResearch Product Faire™ Event at the University of Arizona, Tucson on December 4th 2014.
Laboratory supply companies are invited at the BioResearch Product Faire™ Event to enjoy:
- An engaged and receptive target audience
- Qualified audience and excellent leads
- Educating academic researchers with the newest products and services effectively
- Strategic integrated marketing opportunities
Academic researchers from Tucson are invited to enjoy:
- The newest technology and research information in your research field
- Product samples from relevant exhibitors
- Exchanging research information with your coworkers and friends
- A pizza luncheon with friends
Last year, the BioResearch Product Faire™ Event at the University of Arizona, Tucson attracted 148 attendees. Of these attendees, 41 were purchasing agents, professors and post docs, and 19 were lab managers. These attendees came from 18 different research buildings and 33 on-campus departments.
If your are a laboratory supply company interested in participating in the 12th Annual BioResearch Product Faire™ Event at the University of Arizona at Tucson on December 4th 2014, please click the button below for more information.
National Show Schedule is Available for Researchers and Exhibitors
Biotechnology Calendar, Inc. has been producing on-campus vendor tradeshows for more than 20 years. Each year Biotechnology Calendar, Inc. provides more than 60 the BioResearch Product Faire™ Events at different institutions across the country. Please read the National Show Schedule for 2014 if you are interested in exhibiting at one of those events.